ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $717 | +73.6% | 23,366 | +161.2% | 0.00% | 0.0% |
Q2 2023 | $413 | +15.0% | 8,946 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $359 | -13.3% | 8,946 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $414 | -99.9% | 8,946 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $370,000 | -96.0% | 8,946 | -94.2% | 0.00% | -96.0% |
Q2 2022 | $9,171,000 | -17.8% | 153,716 | 0.0% | 0.05% | -2.0% |
Q1 2022 | $11,163,000 | -13.6% | 153,716 | 0.0% | 0.05% | -3.8% |
Q4 2021 | $12,926,000 | -6.8% | 153,716 | 0.0% | 0.05% | -13.1% |
Q3 2021 | $13,864,000 | +14.4% | 153,716 | +20.9% | 0.06% | +15.1% |
Q2 2021 | $12,124,000 | -16.3% | 127,153 | 0.0% | 0.05% | -22.1% |
Q1 2021 | $14,478,000 | -17.8% | 127,153 | -0.1% | 0.07% | -20.0% |
Q4 2020 | $17,621,000 | +2297.4% | 127,290 | +1322.9% | 0.08% | +2025.0% |
Q3 2020 | $735,000 | +5.0% | 8,946 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $700,000 | +76.3% | 8,946 | 0.0% | 0.00% | +33.3% |
Q1 2020 | $397,000 | +37.4% | 8,946 | +32.1% | 0.00% | +50.0% |
Q4 2019 | $289,000 | -0.3% | 6,773 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $290,000 | -32.6% | 6,773 | 0.0% | 0.00% | -33.3% |
Q2 2019 | $430,000 | -8.5% | 6,773 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $470,000 | +59.9% | 6,773 | 0.0% | 0.00% | +50.0% |
Q4 2018 | $294,000 | -43.1% | 6,773 | 0.0% | 0.00% | -33.3% |
Q3 2018 | $517,000 | -0.8% | 6,773 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $521,000 | +51.0% | 6,773 | 0.0% | 0.00% | +50.0% |
Q1 2018 | $345,000 | +9.9% | 6,773 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $314,000 | -13.0% | 6,773 | 0.0% | 0.00% | -33.3% |
Q3 2017 | $361,000 | -14.3% | 6,773 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $421,000 | -8.3% | 6,773 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $459,000 | -3.6% | 6,773 | 0.0% | 0.00% | -25.0% |
Q4 2016 | $476,000 | -0.8% | 6,773 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $480,000 | +45.0% | 6,773 | 0.0% | 0.00% | +33.3% |
Q2 2016 | $331,000 | -22.8% | 6,773 | 0.0% | 0.00% | -25.0% |
Q1 2016 | $429,000 | -21.1% | 6,773 | +39.6% | 0.00% | -20.0% |
Q4 2015 | $544,000 | +110.9% | 4,850 | +80.9% | 0.01% | +150.0% |
Q3 2015 | $258,000 | -6.2% | 2,681 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $275,000 | – | 2,681 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |